Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond : Episode 5
Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL
Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
EP: 1.Overview of Large B-Cell Lymphoma (LBCL)
EP: 2.Treatment Strategies for Patients with R/R LBCL
EP: 3.CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies
EP: 4.CAR T-Cell Therapy as Second-Line Treatment in LBCL
Now Viewing
EP: 5.Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL
EP: 6.Additional Key Data Updates from ASH 2022 on Treatment of LBCL
EP: 7.Treatment Sequencing in LBCL: Clinical Trial and Real-World Data
EP: 8.Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL
Related Videos
Related Content
